This site is intended only for healthcare professionals resident in Egypt 




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact Us



Clinical Information Clinical Information Burden of meningococcal disease Serogroup distribution Nimenrix® immunogenicity Nimenrix® persistence Nimenrix® dose and administration Real-world impact Summary Important Safety Information Abbreviated Prescribing Information Support and Services Support and Services VideosWebinarsSelf-detail Presentations

Nimenrix® in a nutshell

MenACWY-TT vaccine with demonstrated seroprotection and approved for use from age 6 weeks with no upper age limit

MenACWY-TT vaccine with antibody persistence evaluated for up to 10 years

MenACWY-TT vaccine shown to be immunogenic in immunocompromised population, like patients with anatomical or functional asplenia

Proven non-inferior to monovalent MenC vaccines

Nimenrix® offers coadministration with other routine immunisations for infants, toddlers, and adolescents

Nimenrix® can be prepared and administered in a few easy steps

Safety has been evaluated in more than 10,000 individuals in clinical trials

Find out moreLoading
Find out moreLoading
Find out moreLoading
MenACWY-TT, Meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine.

  1. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777-779.
  2. Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). Egyptian Drug Authority leaflet approval date: 19/10/2022 Revision date: May 2022.
  3. Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review. Infect Dis Ther. 2019;8(3):307-333.
Click here for Nimenrix® Prescribing Information Loading

Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025


Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.